Page 5 - Dohme Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNaoki okamuraAhsan arozullahRoger danseyDrug administrationEuropean society for medical oncologyInternational agency for research on cancerMerck sharp dohme corpAstellas pharma us incMerck co incEuropean commissionCorporate communicationsEuropean medicines agency for padcevNational cancer institutePfizer incHead of oncology development

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on Jan. 26, 2024.

United statesNaoki okamuraAhsan arozullahRoger danseyEuropean medicines agencyPrnewswire astellas pharma incMerck sharp dohme corpCommittee for medicinal products human useMerck co incPfizer incAstellas pharma us incEuropean medicines agency for padcevEuropean commissionDrug administrationEuropean society for medical oncologyAmerican society of clinical oncology

Astellas Pharma Inc : European Medicines Agency Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc : European Medicines Agency Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterNaoki okamuraAhsan arozullahRoger danseyPrnewswire astellas pharma incEuropean medicines agencyMerck sharp dohme corpCommittee for medicinal products human useDrug administrationEuropean commissionEuropean medicines agency for padcevAstellas pharma us incPfizer incMerck co incHead of oncology development

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAhsan arozullahNaoki okamuraRoger danseyEuropean medicines agencyMerck sharp dohme corpCommittee for medicinal products human useEuropean commissionDrug administrationAstellas pharma us incEuropean medicines agency for padcevPfizer incMerck co incExchange commissionNational cancer instituteHead of oncology development

LAVA Therapeutics Announces Collaboration with Merck & Co , Inc , Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr

United statesJoyce allaireMerck coMerck sharp dohme corpExchange commissionMerck co incStephen hurlyChief executive officerChief scientific officerMerck sharpDohme corpSci advisorsProstate cancerMerck coProstate specific membrane antigenDose escalation